The present invention relates to the field of pharmaceutical chemistry, and specifically relates to a fused heterocyclic compound derivative and an application thereof. The fused heterocyclic compound derivative has the structure of general formula (I), and can be used to treat neuropsychiatric diseases.

##STR00001##

Compounds having a structure of formula (I), including stereoisomers and pharmaceutically acceptable salts and solvates thereof:

##STR00001##

wherein R.sub.1 is as defined herein. Such compounds are inhibitors of the vesicular monoamine transporter 2 (VMAT2) and have utility for treating, for example, hyperkinetic disorders. Also disclosed are compositions containing these compounds in combination with a pharmaceutically acceptable carrier or diluent, as well as methods relating to the use in a subject in need thereof.

Compounds having a structure of formula (I), including stereoisomers and pharmaceutically acceptable salts and solvates thereof:

##STR00001##

wherein R.sub.1 is as defined herein. Such compounds are inhibitors of the vesicular monoamine transporter 2 (VMAT2) and have utility for treating, for example, hyperkinetic disorders. Also disclosed are compositions containing these compounds in combination with a pharmaceutically acceptable carrier or diluent, as well as methods relating to the use in a subject in need thereof.

The near infrared absorbing curable composition includes: a compound represented by Formula (1); and a compound having a crosslinking group. In Formula (1), X.sup.1 and X.sup.2 each independently represent O, S, or a dicyanomethylene group, and A and B each independently represent a group represented by Formula (2). In Formula (2), a wave line represents a binding site of Formula (1), Y.sub.S represents a group having active hydrogen, A1 represents an aromatic hydrocarbon ring or an aromatic heterocycle, R.sub.Z represents a substituent, m1 represents an integer of 0 to mA, mA represents an integer representing the maximum number of R.sub.Z's which may be substituted in A1, Y.sub.S may be bonded to A1 or R.sub.Z to form a ring, and R.sub.Z may be bonded to A1 to form a ring.

##STR00001##

The near infrared absorbing curable composition includes: a compound represented by Formula (1); and a compound having a crosslinking group. In Formula (1), X.sup.1 and X.sup.2 each independently represent O, S, or a dicyanomethylene group, and A and B each independently represent a group represented by Formula (2). In Formula (2), a wave line represents a binding site of Formula (1), Y.sub.S represents a group having active hydrogen, A1 represents an aromatic hydrocarbon ring or an aromatic heterocycle, R.sub.Z represents a substituent, m1 represents an integer of 0 to mA, mA represents an integer representing the maximum number of R.sub.Z's which may be substituted in A1, Y.sub.S may be bonded to A1 or R.sub.Z to form a ring, and R.sub.Z may be bonded to A1 to form a ring.

##STR00001##

Compounds having a structure of formula (I), including stereoisomers and pharmaceutically acceptable salts and solvates thereof: ##STR00001##
wherein R.sub.1 is as defined herein. Such compounds are inhibitors of the vesicular monoamine transporter 2 (VMAT2) and have utility for treating, for example, hyperkinetic disorders. Also disclosed are compositions containing these compounds in combination with a pharmaceutically acceptable carrier or diluent, as well as methods relating to the use in a subject in need thereof.

Compounds having a structure of formula (I), including stereoisomers and pharmaceutically acceptable salts and solvates thereof: ##STR00001##
wherein R.sub.1 is as defined herein. Such compounds are inhibitors of the vesicular monoamine transporter 2 (VMAT2) and have utility for treating, for example, hyperkinetic disorders. Also disclosed are compositions containing these compounds in combination with a pharmaceutically acceptable carrier or diluent, as well as methods relating to the use in a subject in need thereof.

It is intended to provide: a compound useful as an amyloid oxidation catalyst which is applicable in vivo and is applicable not only to A peptides but to other amyloids; and a prophylactic or therapeutic drug for an amyloid-related disease, comprising the same. The present invention provides a benzothiazole compound represented by the following formula (1) wherein X represents a halogen atom; R.sup.1 represents an optionally substituted hydrocarbon group; R.sup.2 represents a hydrogen atom or an optionally substituted hydrocarbon group; R.sup.3 and R.sup.4 are the same or different and each represent a hydrogen atom, an optionally substituted hydrocarbon group, an alkoxy group, a halogen atom, an amino group, a nitro group, or a cyano group; R.sup.2 and R.sup.4 optionally together form an alkylene group; and R.sup.5 represents an anion. ##STR00001##

It is intended to provide: a compound useful as an amyloid oxidation catalyst which is applicable in vivo and is applicable not only to A peptides but to other amyloids; and a prophylactic or therapeutic drug for an amyloid-related disease, comprising the same. The present invention provides a benzothiazole compound represented by the following formula (1) wherein X represents a halogen atom; R.sup.1 represents an optionally substituted hydrocarbon group; R.sup.2 represents a hydrogen atom or an optionally substituted hydrocarbon group; R.sup.3 and R.sup.4 are the same or different and each represent a hydrogen atom, an optionally substituted hydrocarbon group, an alkoxy group, a halogen atom, an amino group, a nitro group, or a cyano group; R.sup.2 and R.sup.4 optionally together form an alkylene group; and R.sup.5 represents an anion. ##STR00001##

Provided are a compound which is useful as an in vivo applicable, amyloid-oxygenating catalyst selective for amyloid and applicable not only to an A peptide but also to other amyloids and a drug containing the compound for preventing and/or treating amyloid-related-diseases.

Disclosed is a boron-dipyrrin complex represented by the following formula (1)

##STR00001## wherein X.sup.1 and X.sup.2 are the same or different and each represent a halogenoalkyl group or a halogen atom; R.sup.1 represents a hydrogen atom, an alkyl group, or a group represented by formula (b);

##STR00002## R.sup.2 and R.sup.6 are the same or different and each represent a hydrogen atom or a halogen atom; R.sup.3, R.sup.4, R.sup.5, and R.sup.7 are the same or different and each represent a hydrogen atom, a halogen atom, or an alkyl group; R.sup.8 represents a hydrogen atom or (CH.sub.2).sub.l(Y).sub.m(CH.sub.2).sub.nZ wherein Y represents CO, CONH, or a triazole ring, Z represents a carboxyl group, a sulfonic acid group, or a CO-peptide residue, l and n each represent an integer of 1 to 6, and m represents 0 or 1; R.sup.9 and R.sup.10 are the same or different and each represent a hydrogen atom, an alkyl group, an alkoxy group, a halogen atom, an amino group, a nitro group, or a cyano group; and R.sup.8 and R.sup.10 together optionally form an alkylene group.